This synNotch receptor can detect tumor-specific antigens such as EGFRvIII expressed on glioblastomas specifically and myelin oligodendrocyte glycoprotein expressed in the central nervous system specifically, and can then induce the expression of tandem CARs targeting ephrin type A receptor 2 (EphA2) and IL13Rα2 as killing targets to achieve the activation of CAR-T cells. Here, EPHA2 is linked to neoplasm.